Clinical trials: Coronary Vessel
Acute Coronary Syndrome
BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)
The objective of this study is to investigate whether intravenous administration (injected into a vein) of acetylsalicylic acid (Aspirin) in doses of 250 and 500 mg is superior to oral treatment of ACS with tablets containing 300…
- Trial name
- ACUTE (NCT00910065)
- Testing
- D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV, D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV, Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet
- Where
- 37 sites in China, Germany and 2 more
- Volunteers
- 270 people
- Sponsor
- Bayer
Ischemic Heart Failure, Ischemic Heart Disease
Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack.
Study to examine the safety and effectiveness of implanted skeletal muscle cells (cells removed from the thigh muscle) into scarred areas of heart muscle after heart attack.
- Conditions
- Ischemic Heart Failure, Ischemic Heart Disease, Ischemic Cardiomyopathy
- Trial name
- NCT00102128
- Testing
- Cellular Therapy (Cultured Autologous Skeletal Myoblast Transplantation)
- Where
- 28 sites in Belgium, France and 4 more
- Sponsor
- Genzyme, a Sanofi Company
Coronary Heart Disease
Study to Detect Biomarker Gradients in Coronary Arteries Using the Liquid Biopsy System
The Liquid Biopsy System (LBS) is a new catheter (thin tube) designed for sampling blood directly from coronary arteries. These arteries supply blood to muscles of the heart and can become blocked by 'plaques' leading to chest…
- Trial name
- CS1 (NCT02119767)
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- PlaqueTec Ltd
Hypertension,Essential, Systolic Hypertension
Cardiac Neuromodulation Therapy (CNT) "Washout" Sub-Study
This washout protocol is structured as a sub-study for patients willing to participate after finishing the double blind randomised phase of the clinical trial, NCT02837445. Devices will be turned off for a week approximately.
- Trial name
- NCT05086523
- Testing
- Programmable Hypertension Control (BackBeat Moderato), Pacing (BackBeat Moderato)
- Where
- 6 sites in Czechia, Hungary and 1 more
- Volunteers
- 28 people
- Sponsor
- BackBeat Medical Inc
Coronary Artery Disease
FIM-NL - First-in-Man Study (Netherlands Part) With Sirolimus Coated Modified BX Velocity Stent
The objective of this study is to assess the performance and safety of a formulation of the antiproliferative agent, sirolimus coated on modified Bx VELOCITY Balloon-Expandable Stent mounted on the Raptor Over The Wire (OTW)…
- Trial name
- NCT00233818
- Testing
- Sirolimus-coated Bx VELOCITY Stent
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
The COMPLETE Study
The COMPLETE study is a single-centre, investigator-initiated study of patients with an indication for invasive coronary angiography with CCTA performed during the diagnostic evaluation.
- Trial name
- COMPLETE (NCT06205810)
- Where
- Belgium
- Volunteers
- 250 people
- Sponsor
- CoreAalst BV
Myocardial Ischemia, Hypertension
ARCHIPELAGO: Irbesartan in Patients With Acute Coronary Syndrome Without ST Segment Elevation
Primary Objective The main objective of this study is to assess if a two-month regimen of irbesartan in patients hospitalized for acute coronary syndrome without ST segment elevation can reduce inflammation markers (ie hsCRP), in…
- Trial name
- NCT00296218
- Testing
- Irbesartan
- Where
- 11 sites in United States, Belgium and 9 more
- Volunteers
- 440 people
- Sponsor
- Sanofi
Coronary Artery Disease
Compare Sirolimus Coated Balloon Catheter With Paclitaxel Coated Balloon Catheter in De Novo Coronary Bifurcated Lesions
The purpose of this study is to evaluate the efficacy and safety of Microport sirolimus drug coated balloon catheter for the treatment of coronary bifurcation lesions.
- Trial name
- PROMISE-BIF (NCT04918615)
- Testing
- PCI
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Arteriosclerosis
A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)
The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce the atherosclerosis (fatty deposits) in your arteries
- Trial name
- NCT00240318
- Testing
- Rosuvastatin calcium
- Where
- 61 sites in United States, Australia and 6 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Atherosclerosis
A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
The main purpose of the study is to evaluate the efficacy of selnoflast compared with placebo in participants with atherosclerosis, at high-risk for major adverse cardiovascular event (MACE), who are currently on standard-of-care…
- Trial name
- RIVULET (NCT07448038)
- Testing
- Selnoflast
- Where
- 25 sites in United States, Canada
- Volunteers
- 162 people
- Sponsor
- Genentech, Inc.
Myocardial Infarction, Heart Failure
A Study of VentriGel in Post-MI Patients
This Phase I, open label, study will investigate the effects of VentriGel injection in patients who have experienced a first, large ST elevation myocardial infarction (STEMI) treated by PCI within the past 3 years and have…
- Conditions
- Myocardial Infarction, Heart Failure, Left Ventricular Remodeling
- Trial name
- NCT02305602
- Testing
- VentriGel
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Ventrix, Inc.
Left Atrial Appendage Exclusion
AtriCure Exclusion of the LAA in Patients Undergoing Concomitant Cardiac Surgery
Prospective, non-randomized trial to evaluate the safety and efficacy of the LAA Exclusion Device (Clip) for the exclusion of the LAA via epicardial tissue approximation.
- Trial name
- EXCLUDE (NCT00779857)
- Testing
- AtriCure LAA Exclusion System
- Where
- 7 sites in United States
- Volunteers
- 70 people
- Sponsor
- AtriCure, Inc.
Coronary Artery Diseases
BIOFLOW III Satellite-Italy Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). 500 subjects will be enrolled in this registry.
- Trial name
- NCT02028728
- Where
- 18 sites in Italy
- Volunteers
- 609 people
- Sponsor
- Biotronik Italia S.p.A.
Myocardial Infarction
A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)
Primary objective: to evaluate the procoagulant effect of TNK-tPA compared to rt-PA and streptokinase, administered to patients with AMI, by measuring the concentration of TAT at 2 hours after the start of treatment versus…
- Trial name
- NCT02182011
- Testing
- Tenecteplase, Alteplase, Streptokinase
- Volunteers
- 49 people
- Sponsor
- Boehringer Ingelheim
Coronary Disease, Coronary Artery Disease
ABSORB Clinical Investigation, Cohort A (ABSORB A) Everolimus Eluting Coronary Stent System Clinical Investigation
Prospective, open-labeled First in Man Clinical Investigation enrolling patients with visually estimated nominal vessel diameter of 3.0 mm receiving a single 3.0 x 12 mm or 3.0 x 18 mm BVS EECSS containing 98 microgramme per cm²…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- ABSORB A (NCT00300131)
- Testing
- Bioabsorbable Everolimus Eluting Coronary Stent
- Where
- 4 sites in Denmark, Netherlands and 2 more
- Volunteers
- 30 people
- Sponsor
- Abbott Medical Devices
Angina, Stable, Angina, Unstable
Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy
The purpose of this study is to determine whether patients undergoing coronary intervention that also require oral anticoagulation, treatment with the COBRA PzF stent plus 14-day dual anti-platelet therapy (DAPT) has higher…
- Conditions
- Angina, Stable, Angina, Unstable, Anticoagulants
- Trial name
- COBRA-REDUCE (NCT02594501)
- Testing
- COBRA PzF, Drug Eluting Stent
- Where
- 48 sites in United States, Belgium and 6 more
- Volunteers
- 996 people
- Sponsor
- CeloNova BioSciences, Inc.
Myocardial Infarction
Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction
The purpose of this study is to determine the dose of drug which is most effective in the delineation of dead heart muscle.
- Trial name
- NCT00310544
- Testing
- Magnevist (Gadopentetate dimeglumine, BAY86-4882)
- Where
- 7 sites in United States, Argentina
- Volunteers
- 73 people
- Sponsor
- Bayer
Coronary Heart Disease, Multi Vessel Coronary Artery Disease
Optilene® Suture for Coronary Artery Bypass Graft Surgery
The study is a voluntary study, initiated by B. Braun to collect clinical data for Optilene® suture concerning its key indication.
- Trial name
- OPTICABG (NCT02546557)
- Testing
- Coronary Artery Bypass Graft surgery
- Where
- 4 sites in Germany, Italy and 2 more
- Volunteers
- 245 people
- Sponsor
- Aesculap AG
Coronary Artery Disease
Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions
The purpose of the study is to assess the safety and efficacy of the Orsiro® Mission 48- mm Sirolimus-Eluting Coronary Stent System in the treatment of subjects with atherosclerotic lesion(s) >36 mm and ≤ 44 mm in length (by…
- Trial name
- BIOFLOW-48 (NCT06779630)
- Testing
- Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System
- Where
- 23 sites in United States, Austria and 4 more
- Volunteers
- 150 people
- Sponsor
- Teleflex
Overweight, Obesity
A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World
This study aims to evaluate the association of once-weekly semaglutide with the risk of cardiovascular (CV) and other obesity-related clinical outcomes in three study populations (Heart failure (HF), clinical Atherosclerotic…
- Conditions
- Overweight, Obesity, Heart Failure (HF), Atherosclerotic Cardiovascular Disease (ASCVD)
- Trial name
- NCT07141914
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 285,327 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.